APA (7th ed.) Citation

Kessel, A. C., Kim, H., Brown, P. D., Lehrer, E. J., Laack, N. N., Mahajan, A., . . . Kowalchuk, R. O. (2026). Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma. Cancer (0008543X), 132(11), 1. https://doi.org/10.1002/cncr.70463

Chicago Style (17th ed.) Citation

Kessel, Adam C., et al. "Cost‐effectiveness of Vorasidenib in Treatment of Isocitrate Dehydrogenase–mutated Low‐grade Glioma." Cancer (0008543X) 132, no. 11 (2026): 1. https://doi.org/10.1002/cncr.70463.

MLA (9th ed.) Citation

Kessel, Adam C., et al. "Cost‐effectiveness of Vorasidenib in Treatment of Isocitrate Dehydrogenase–mutated Low‐grade Glioma." Cancer (0008543X), vol. 132, no. 11, 2026, p. 1, https://doi.org/10.1002/cncr.70463.